Woodstock: Owen Mumford wins Queen's Award for Enterprise

Owen Mumford has been recognised as a winner of the Queen’s Award for Enterprise (Innovation) - the UK’s highest accolade for business success. The innovation award celebrates organisations showing outstanding and/or sustained commercial success over a period of years.

 

Owen Mumford received the award for ‘Innovation’, in recognition of the new innovations in medical device design and manufacturing the company has developed to improve quality of life, encourage adherence to treatment and reduce healthcare costs. Making a world of difference, to a world of people.

 

With a 65-year history of medical device firsts, Oxfordshire-based Owen Mumford offers innovations in diagnostic sampling to drug delivery from a broad base of proven self-injection and blood sampling platform devices and intellectual property.

 

Owen Mumford’s extensive research, design and manufacturing capabilities produce leading-class medical devices that are used by a worldwide audience – with over 85% of their products exported to more than 60 countries. They are committed to bringing life-saving and life-changing devices to new markets around the globe.

 

The award acknowledged Owen Mumford’s developments in injection pen needles specifically Unifine Pentips Plus. The global increase in diabetes has seen a concurrent increase in demand for pen devices with needles for injection. While single use of the pen needle is the recommendation, it is difficult to effectively educate patients about best practice and the ease of pen needle removal and disposal is a major barrier to compliance. The innovative product all-in-one pen needle is an integrated device with two chambers, one containing a new pen needle, the other providing a more convenient removal chamber for interim disposal.

 

The development enables users to fit a new needle easily and dispose of the old one responsibly. Following development of the innovation, Owen Mumford conducted a user evaluation study and identified that adherence in using a new pen needle for each injection increased by 61% when compared to their needle change behaviour with their previous standard pen needle. Commercially, sales of the device have increased by 52% over the past two years.

 

Jarl Severn, managing director at Owen Mumford, said: “Receiving our Queen’s Award for Innovation is particularly rewarding as it highlights how everything we do at Owen Mumford is about making a world of difference. Through our work, we seek to improve quality of life, encourage adherence to treatment and reduce healthcare costs. The Innovation Award celebrates organisations showing outstanding and or sustained commercial success over a period of years and we are delighted that our 65-year history of world firsts in device solutions have been recognised by the former prime minister and the Queen.

 

“I’d like to take this opportunity to thank all our associates who have contributed to our innovative product and to our customers for all of their on-going support, custom and loyalty.”